Get started
Author

Ted Drogendijk

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial
2012 · Vik Khullar, Gerard Amarenco, et al. · European Urology · 430
Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder
2012 · Christopher R. Chapple, Steven A. Kaplan, et al. · European Urology · 363
Randomized, Double-blind Placebo Controlled Trial of the Once Daily Antimuscarinic Agent Solifenacin Succinate in Patients With Overactive Bladder
2004 · L. CARDOZO, M. LISEC, et al. · The Journal of Urology · 335
A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial
2005 · C.R. Chapple, R. Martinez-Garcia, et al. · European Urology · 327
A phase II dose-ranging study of mirabegron in patients with overactive bladder
2013 · On behalf of the Dragon Investigator Group, Christopher R. Chapple, et al. · International Urogynecology Journal · 137
PDF
Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double‐blind, placebo‐controlled, rising‐dose trial
2008 · Linda Cardozo, Elke Heßdörfer, et al. · British Journal of Urology · 132
Combination Therapy with Solifenacin and Tamsulosin Oral Controlled Absorption System in a Single Tablet for Lower Urinary Tract Symptoms in Men: Efficacy and Safety Results from the Randomised Controlled NEPTUNE Trial
2013 · Philip van Kerrebroeck, Christopher Chapple, et al. · European Urology · 104
Long-term Safety and Efficacy of Single-tablet Combinations of Solifenacin and Tamsulosin Oral Controlled Absorption System in Men with Storage and Voiding Lower Urinary Tract Symptoms: Results from the NEPTUNE Study and NEPTUNE II Open-label Extension
2014 · Marcus J. Drake, Christopher Chapple, et al. · European Urology · 80
Single dose pharmacokinetics and absolute bioavailability of mirabegron, a ?3-adrenoceptor agonist for treatment of overactive bladder
2012 · Charlotte Eltink, Jennifer Lee, et al. · International Journal of Clinical Pharmacology and Therapeutics · 55
Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms
2013 · Christopher R. Chapple, Marcus J. Drake, et al. · British Journal of Urology · 39
Severity of overactive bladder symptoms and response to dose escalation in a randomized, double‐blind trial of solifenacin ( SUNRISE )
2013 · Linda Cardozo, Gerard Amarenco, et al. · British Journal of Urology · 36
The effects of an ACTH (4?9) analogue on development of cisplatin neuropathy in testicular cancer: A randomized trial
1994 · J. M. A. Gerven, A. Hovestadt, et al. · Journal of Neurology · 33
Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine
1994 · L.C. Pronk, A.S.Th. Planting, et al. · European Journal of Cancer · 28
Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain
1994 · The European Velnacrine Study Group, L. Harms, et al. · Journal of Neurology · 13
Validation of the Patient Perception of Intensity of Urgency Scale in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
2014 · Susan D. Mathias, Ross D. Crosby, et al. · Value in Health · 11
PDF
683 Randomised, double-blind, active-controlled phase III study to assess the long-term safety and efficacy of mirabegron in overactive bladder (OAB)
2012 · C.R. Chapple, S. Kaplan, et al. · European Urology Supplements · 11
YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder
2003 · L. Cardozo, I. Kuzmin, et al. · European Urology Supplements · 7
UP-2.35: Total urgency score (TUS) as a measure of frequency and urgency in SUNRISE
2010 · L. Cardozo, J. Mikulas, et al. · Urology · 6
1089 Quality of life analyses from NEPTUNE, a phase 3 trial of combination therapy with tamsulosin OCAS™ and solifenacin in men with lower urinary tract symptoms
2013 · M.J. Drake, R. Sokol, et al. · European Urology Supplements · 3
MP-05.01 Evaluating the Efficacy and Safety of Fixed-Dose Combinations of Tamsulosin OCAS™ and Solifenacin in Male LUTS with Storage and Voiding Symptoms: An Overview of the NEPTUNE Trial
2011 · M. Drake, M. Speakman, et al. · Urology · 3
POS-01.134: Responses to solifenacin in patients >65 years and ≤65 years with overactive bladder syndrome: post-hoc results from the randomised, double-blind STAR study
2007 · C.R. Chapple, T. Drogendijk, et al. · Urology · 3
The efficacy of solifenacin 5/10mg on ‘urgency’ endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study
2008 · Linda Cardozo, Ted Drogendijk, et al. · ics.org · 2
The patient perception of intensity of urgency scale (PPIUS): Its validation in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)
2013 · S.D. Mathias, R. Crosby, et al. · Value in Health · 1
PDF
772 Patient satisfaction with the safety and efficacy of fixed-dose combinations of solifenacin and tamsulosin OCAS™: Results from the NEPTUNE II study
2014 · M.J. Drake, C. Chapple, et al. · European Urology Supplements
Evaluating the long-term safety and efficacy of fixed dose combinations of solifenacin and tamsulosin OCAS™ in male LUTS with storage and voiding symptoms: results from the NEPTUNE II study
2012 · Marcus J. Drake, Roman Sokol, et al. · ics.org
Works count: 32
Citation count: 2,159
H-index: 13
I10-index: 16
Year
Topic
Type